Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC73943Polθ/PARP-IN-1纯度: >99.00%
Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。
- GC73996PROTAC AR/AR-V7 degrader-1CAS: 2841308-96-9纯度: >98.00%
PROTAC AR/AR-V7 degrader-1(27c)是一种基于PROTAC的双AR AR-V7降解器,AR和AR-V7的DC50值分别为2.67和2.64μM。
- GC74029ASCT2-IN-1CAS: 3032651-18-3纯度: >98.00%
ASCT2-IN-1(化合物20k)是一种ASCT2抑制剂,在A549和HEK293细胞中的IC50值分别为5.6 μM和3.5 μM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC73868 | WD6305 TFA | - | >98.00% | |
WD6305 TFA是一种有效的mettl3靶向PROTAC降解剂。 | ||||
| GC73881 | PRO-6E | 2353493-69-1 | >99.00% | |
PRO-6E是一种基于小脑配体的口服活性PROTAC,在MKN-45细胞中,在1 μM时可诱导MET降解,最大降解率为81.9%。 | ||||
| GC73893 | BLU-222 | 2888704-84-3 | >98.00% | |
BLU-222是一种口服活性高选择性CDK2抑制剂。 | ||||
| GC73900 | HA-9104 | 2412367-83-8 | >98.00% | |
HA-9104是一种有效的选择性抑制剂,通过几乎靶向UBE2F的V30口袋来抑制cullin-5 nedylation。 | ||||
| GC73918 | BAY 249716 | 696628-24-7 | >99.00% | |
BAY 249716稳定所有三种p53蛋白变体。 | ||||
| GC73925 | YSR734 | 3032969-58-4 | >98.00% | |
YSR734(化合物21)是一种共价HDAC抑制剂,对HDAC1、HDAC2和HDAC3的IC50值分别为110 nM、154 nM和143 nM。 | ||||
| GC73928 | BDM19 | 500273-31-4 | >98.00% | |
BDM19并单独或与BCL-2/BCL-XL抑制剂Navitoclax联合诱导细胞凋亡。 | ||||
| GC73932 | WK369 | - | >99.00% | |
WK369是一种新型的BCL6小分子抑制剂,具有良好的抗卵巢癌生物活性,可诱导细胞周期阻滞和细胞凋亡。 | ||||
| GC73935 | CBI1 formic | - | 不显示 | |
CBI1 formic是一种共价BAX抑制剂。 | ||||
| GC73939 | ATPase-IN-3 | 1134203-12-5 | >99.00% | |
ATPase-IN-3(化合物6)是一种atp酶抑制剂。 | ||||
| GC73940 | BFC1108 | 692774-37-1 | >98.00% | |
BFC1108是一种小分子Bcl-2功能转换器。 | ||||
| GC73943 | Polθ/PARP-IN-1 | - | >99.00% | |
Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。 | ||||
| GC73950 | SC912 | - | >99.00% | |
SC912是AR-V7抑制剂(IC50 = 0.36 μM)。 | ||||
| GC73973 | MY-1442 | 3050871-87-6 | >99.00% | |
MY-1442(I-3)是微管蛋白聚合抑制剂。 | ||||
| GC73980 | GGTI-2417 | 501010-05-5 | >98.00% | |
GGTI-2417是GGTase I的强效选择性抑制剂。 | ||||
| GC73982 | NSD-IN-3 | 744260-15-9 | >98.00% | |
NSD-IN-3(化合物3)是一种强效的核受体结合SET结构域(NSD)抑制剂。 | ||||
| GC73986 | MX106-4C | - | >98.00% | |
MX106-4C是一种选择性杀死abcb1阳性结直肠癌细胞的survivin抑制剂。 | ||||
| GC73990 | SDU-071 | - | >98.00% | |
SDU-071是BRD4-p53抑制剂的强效口服活性抑制剂。 | ||||
| GC73995 | XL44 | 2637949-91-6 | >98.00% | |
XL44是一种hRpn13结合物,可诱导hRpn13依赖性细胞凋亡,并通过pclaf依赖性机制限制细胞活力。 | ||||
| GC73996 | PROTAC AR/AR-V7 degrader-1 | 2841308-96-9 | >98.00% | |
PROTAC AR/AR-V7 degrader-1(27c)是一种基于PROTAC的双AR AR-V7降解器,AR和AR-V7的DC50值分别为2.67和2.64μM。 | ||||
| GC74001 | TS-24 | 1563260-97-8 | >98.00% | |
TS-24是组织蛋白酶S的抑制剂,IC50为4.3μM。 | ||||
| GC74007 | SelSA | 1225038-92-5 | >99.00% | |
SelSA是一种选择性的口服活性组蛋白去乙酰化酶6 (HDAC6)抑制剂,IC50为56.9 nM。 | ||||
| GC74024 | BPU | - | >99.00% | |
BPU在亚g1期阻止细胞周期进程。 | ||||
| GC74029 | ASCT2-IN-1 | 3032651-18-3 | >98.00% | |
ASCT2-IN-1(化合物20k)是一种ASCT2抑制剂,在A549和HEK293细胞中的IC50值分别为5.6 μM和3.5 μM。 | ||||
